These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8585284)

  • 1. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
    Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I
    Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
    Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
    Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
    Yoo YC; Saiki I; Sato K; Azuma I
    Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
    Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
    Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo effects of MDP-Lys(L18) on mouse megakaryocyte progenitor cells (CFU-Meg).
    Komiya I; Kuriya S; Akahane K; Nomura T
    Exp Hematol; 1992 May; 20(4):517-22. PubMed ID: 1568468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine.
    Yoo YC; Yoshimatsu K; Koike Y; Hatsuse R; Yamanishi K; Tanishita O; Arikawa J; Azuma I
    Vaccine; 1998; 16(2-3):216-24. PubMed ID: 9607033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
    Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
    Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18).
    Akasaki M; Takashi T; Kita Y; Tsukada W
    Agents Actions; 1987 Oct; 22(1-2):144-50. PubMed ID: 3318323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of non-specific resistance to infection by muroctasin.
    Otani T; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans.
    Azuma I; Otani T
    Med Res Rev; 1994 Jul; 14(4):401-14. PubMed ID: 8084203
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues.
    Saiki I; Saito S; Fujita C; Ishida H; Iida J; Murata J; Hasegawa A; Azuma I
    Vaccine; 1988 Jun; 6(3):238-44. PubMed ID: 2844032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin.
    Yamaguchi F; Akasaki M; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):980-3. PubMed ID: 3263869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adjuvant effect of a muramyl dipeptide (MDP) analog on temperature-sensitive Salmonella mutant vaccine.
    Onozuka K; Shinomiya H; Cho N; Saito-Taki T; Nakano M
    Int J Immunopharmacol; 1989; 11(7):781-7. PubMed ID: 2689364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
    Nagao S; Sato K; Osada Y
    Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenicity study of muroctasin.
    Yamaguchi F; Hattori H; Wagai N; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
    Koike Y; Yoo YC; Mitobe M; Oka T; Okuma K; Tono-oka S; Azuma I
    Vaccine; 1998 Dec; 16(20):1982-9. PubMed ID: 9796054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer.
    Yanagawa H; Haku T; Takeuchi E; Suzuki Y; Nokihara H; Sone S
    Lung Cancer; 2000 Feb; 27(2):67-73. PubMed ID: 10688489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental and clinical studies on the effects of synthetic muramyldipeptide derivatives on viral and opportunistic infections.
    Yamamura Y; Ishihara C; Hamada N; Yamamoto K; Azuma I
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):11-4. PubMed ID: 3010013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
    Ishihara C; Yamamoto K; Hamada N; Azuma I
    Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice.
    Nakajima R; Ishida Y; Yamaguchi F; Otani T; Ono Y; Nomura M; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):986-92. PubMed ID: 3263871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.